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ABSTRACT
BACKGROUND: Multiple sclerosis(MS) is an acquired chronic demyelinating disease of central nervous system is a 
leading cause of non-traumatic disability in young with significant socioeconomic impact. 
The aim of this study was to provide a comprehensive review of all available data of MS in Pakistan.
METHODS: A comprehensive literature search was performed using Medline ®, Scopus, Embase, Cochrane library 
and PakMedinet. There are no nationwide prevalence or incidence reports from Pakistan and no population based 
surveys.
  
RESULTS: 15 case series were analyzed. 708 patients were found. Revised McDonald criteria of 2010 was the most 
widely used diagnostic criteria in the studies. Female to male ratio of 1.6 was observed. The mean age of onset of 
disease was 29 years.
 
CONCLUSION: Population based surveys are lacking in Pakistan and most of its South Asian neighbors. Real world 
data in the form MS registries is being increasingly recognized as an important source of provision of epidemiological 
data of MS. Establishing MS registry can prove to be a milestone in formation of MS related health care policy and 
improving the standard of MS care in Pakistan. 
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R E V I E W  A R T I C L E
INTRODUCTION: Multiple sclerosis (MS) is an acquired 
chronic inflammatory demyelinating disease of the 
central nervous system.1    MS is a leading cause of 
non-traumatic neurological disability in young patients, 
with a significant resultant social and economic impact, 
as well as potential life time dependence.2,3
MS predominantly affects women. The estimated 
female to male ratio of MS incidence has increased 
from 1.4:1 to 2.3:1 as determined in a systematic 
review of epidemiological studies.4
There is considerable geographical variation in 
incidence and prevalence of MS. Kurtzke5 described 
three geographical zones according to prevalence of 
MS: (1) high frequency >30/100,000, (2) medium 
frequency 5-25/100,000, and (3) low frequency 
<5/100,000. White populations constitute most of the 
high and medium risk areas5. The GBD 2016 Multiple 
Sclerosis Collaborators estimated the worldwide 
prevalence of MS to be 22,21188 in 2016.6 The 
highest reported prevalence was found to be in North 
America, Western Europe and Australia.6 A substantial 
increase of 10.4 % in prevalence was also noted since 
19906. 
South Asia has been considered to be a low prevalence 
zone.7,8 However recent trials have shown an increasing 
prevalence in this region as well. Etemadifar M et al.9 in 
their systematic review demonstrated that incidence 
and prevalence of MS has increase in Iran, and ranges 
from medium to high frequency distribution and not in 
5 2P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
MULTIPLE SCLEROSIS IN PAKISTAN AND NEED FOR 
MULTIPLE SCLEROSIS REGISTRY
Haris Majid Rajput1,3, Mohammad Wasay2,3, Mazhar Badshah1,3, Muhammad Hassan1,4
1.Pakistan Institute of Medical Sciences, Islamabad, Pakistan,  2.Aga Khan University, Karachi, Pakistan
3.Consultant Neurologist, 4.Neurology Resident
Correspondence to: Haris Majid Rajput, Department of Neurology, Pakistan Institute of Medical Sciences, Islamabad, 44,000, Pakistan.  Email: harismajid@gmail.com
Date of submission: October 12, 2018 Date of revision: December 22, 2018 Date of acceptance: December 26, 2018
V O L .  1 4  ( 1 )   J A N U A R Y- M A R C H  2 0 1 9
5 3P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S V O L .  1 4  ( 1 )   J A N U A R Y- M A R C H  2 0 1 9
the low frequency zone as previously suggested.9 In this review, we have tried to cover all studies conducted in Pakistan 
related to MS. 
METHODS
A literature search of Medline ®, Scopus, Embase, Cochrane library and PakMedinet was made using keywords 
`multiple sclerosis, prevalence, incidence, epidemiology, Pakistan and its various cities. We searched for papers 
published before March 25, 2019. The title and abstract of all literatures recognized by the databases were reviewed. 
The data from various articles was entered into a tabulated form purpose of comparison with a focus number of 
patients, study setting, diagnostic criteria used, gender ratio and age of onset. 
Fig. 1. Flow diagram of Methods
RESULTS
The result obtained a total of 94 articles (fig. 1). No population based study or registry was found. Duplicate entries 
were removed. 60 articles were assessed for eligibility after removing articles with irrelevant titles or abstracts. Case 
reports and records of immigrant population from Pakistan to various countries were excluded. 
15 case series were included and data entered in tabulated form (table 1).
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   Table 1: Characteristics of MS in Pakistan
A net total of 708 patient’s data was available. Four out of the 15 records were multicenter hospital based studies, 
whereas the rest were all single center studies. 
Revised McDonald criteria of 2010 was the most widely used diagnostic criteria in the studies. Poser criteria was used 
in one study. There are no nationwide prevalence or incidence reports from Pakistan.  Female predominance was seen 
consistently in most of the records, with a net female to male ratio of 1.6. Ali A et al.22 showed a slight male 
predominance and another study showed equal distribution amongst males and females.20 The mean age of onset of 
disease was available in only 6 records and was estimated to be 29 years. 
DISCUSSION
This article provides a systematic review of all existing data which has been published and is available online regarding 
Multiple sclerosis in Pakistan. Unfortunately like most other non-infectious diseases, there has been no 
epidemiological study conducted in south Asia to determine prevalence, incidence, gender and age distribution of 
MS.25 The data available is only hospital based case series and only one such study was multicenter with over 100 
patients.12 All other patient cohorts are of much lesser number. It has also been found that since these were not 
targeted epidemiological studies, their utilization for extracting any meaningful epidemiological data is severely 
restricted. Pakistan’s largest south Asian neighbor, India also lacks any large epidemiological study.25 Similar gender 
distribution and mean age of onset was found by Pandit L et al.26 in India as seen in our article (table 2).
Table 2: Comparison of characteristics of MS in Southern Asia in internationally published Multicenter 
Cohort studies from Pakistan, India and Iran
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No published data from neighboring Afghanistan was available for comparison.25 Pakistan’s other neighbor from 
Southern Asia Iran has the largest database of MS patients in this region.25 Iran’s largest data cohort published by 
the Ministry of health, has shown a medium frequency prevalence of 8.35 in 100,000 and a large female to male ratio 
of 3.48 to 1.25,27
The highest level of evidence for clinical decision making in MS comes from randomized control trials (RCT), systematic 
reviews and meta-analyses.28 They provide evidence on efficacy and safety and are crucial for regulatory approval. In 
situations where it might not be feasible to perform an RCT, high quality evidence can be generated from data collected 
in the real world clinical settings such as registries and health administrative databases.28 Registries are databases that 
result from prospective, observational cohort studies aimed to collect individualized disease specific data. The main 
purpose of establishing a registry is to improve the delivery of health care and enhance our knowledge regarding the 
disease by collecting information on a standardized format. Randomized control trials (RCT) although provide the 
highest quality of data but their application gets limited in real world in several situations because of strict inclusion 
and exclusion criteria, cost of conducting an RCT and preferential focus of RCT on treatment efficacy vs provision of 
health care.  Registries have the advantage of following up patients for a longer duration of time as compared to RCT.29 
[fink 2016] Data variables in MS registries range from personal data, clinical phenotypes, account of relapses, 
radiological data, MS related clinical outcome measures, treatment adverse events and quality of life measures and 
data of comorbidities,28,30 Registries do have their own sets of limitations. Problems with registries require active 
participation on the part of patient and the health care provider. Registries are also filled with inherent biases due to 
non-randomized sample collection. Over 700,000 patient of MS have been collected in various registries across 
Europe.31 MSBase is the biggest multinational MS registry which started enrollment back in 2003.32,33 It is active 
across 35 countries with over 60,000 patients included in the registry. (table. 3)
Table 3. Examples of MS registries
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a.  Home to MSBase
b.  www.msbase.org (accessed March, 2019)
c.  www.ofsep.org (accessed October, 2018)
d.  www.msregister.de  (accessed January, 2017)
e.  https://vap.carmona.se/open/msvap/tabell/antal_reg/ (accessed December, 2017)
f.  www.rigshospitalet.dk/english/departments/neuroscience-centre/department-of-neurology/research
 /the-danish-multiple-sclerosisregistry (accessed January, 2017)
The MS registries not only provide a solid clinical platform for MS research, but also helps in management of MS 
patients. Just to give an example, the Swedish MS registry (SMSreg), has provided data for over 100 scientific 
publications and had provided real world evidence in long term effective MS disease modifying agents.34
There has been a global trend towards formation of national MS registries in most of the developed countries. 
Formation of an MS registry in a resource limited and densely populated country like Pakistan can serve as the first 
step in the long journey towards managing MS as per the established standards of care. Determining local MS 
epidemiology will assist in prognostication of disease, resource allocation and planning of national health services for 
MS and other acquired demyelinating diseases.
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